Transplantation & Cellular Therapy Meetings | Conferences

Orca-T Achieves Impressive Outcomes in Hematologic Malignancies

February 11, 2021

Data presented during the 2021 Transplantation and Cellular Therapy Meeting showed that treatment with Orca-T, achieved a significant reduction in cases of graft-versus-host disease and other impressive outcomes.

Beti-Cel Shows Good Activity in Transfusion-Dependent Children With Beta-Thalassemia

February 10, 2021

Results from 2 phase 3 clinical trials showed that use of the investigational gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients under the age of 18 years with transfusion-dependent beta-thalassemia.

Maximum Dose of Ruxolitinib Peri-transplant Is Safe and Feasible Treatment For Patients With Myelofibrosis

February 10, 2021

Data from a prospective pilot trial presented at the 2021 Transplantation and Cellular Therapy Meetings show that a maximum dose of 10 mg of ruxolitinib given peri-transplant is a safe and feasible treatment for patients with myelofibrosis.

Axi-Cel Treatment Outcomes Correlate With Response to Prior Therapy in Refractory Large B-Cell Lymphoma

February 09, 2021

Treatment with axicabtagene ciloleucel is less likely to induce responses in patients with refractory large B-cell lymphoma who have never achieved a complete response to any line of prior therapy, according to findings from a single-center retrospective analysis.

Narsoplimab Demonstrates Clinical Activity in High-Risk HSCT-TMA

February 09, 2021

In a pivotal phase 2 trial, administration of narsoplimab to patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy led to impressive responses and a favorable survival benefit.